STML News and Press, Stemline Therapeutics Inc. From 01/14/20

Stemline Therapeutics (NASDAQ: STML )  -22%  on preliminary Q4 revenue. More news on: Stemline Therapeutics, Inc., Avinger, Inc., DURECT Corporation, Stocks on the move, Read more ...

Stemline Therapeutics (NASDAQ: STML ) -20.4% after-hours after announcing preliminary net revenues for Q4 and the full year. More news on: Stemline Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced preliminary net revenues for 2019, as well as outlined key BP...

NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that management will present at the 38 th Annual J.P. Morgan...

The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...

Christmas works like glue, it keeps us all sticking together ." - Rosie Thomas Today, we profile two ' Tier 3 ' names that have been gaining momentum as 2019 comes to a close. Both should see their recently approved products have a significant sales ramp up in 2020 and thus shareholders...

Stemline Therapeutics (NASDAQ: STML ) +3% pre-market after Cantor Fitzgerald initiates coverage with an Overweight rating and $18 price target, saying Elzonris could be a "pipeline in a product" for the company and is underappreciated by investors. More news on: Stemline Therapeutics, ...

Shares of Stemline Therapeutics ( STML ) have lost a third of their value since my August article recommended buying shares given the fact that the Q2 report showed progress on multiple fronts. Recently, at the ASH (American Society of Hematology) annual meeting, the company unveiled prom...

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented data from ELZONRIS ® (tagraxofusp) Phase 1/2 clinical trials ...

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced the appointment of Robert M. Francomano as Chief Commercial O...